The North America immunosuppressant drugs market is estimated to project a CAGR of 3.19% during the forecast period, 2019-2028. The factors driving the growth of the market are the growing government funding for R&D and the prevailing autoimmune diseases like Crohn’s disease and irritable bowel syndrome. The countries analyzed in the North America immunosuppressant drugs market growth evaluation are the United States and Canada. In the United States, the cornea is the majorly transplanted tissue.
NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET FORECAST 2019-2028
The North America immunosuppressant drugs market is estimated to project a CAGR of 3.19% during the forecast period, 2019-2028. The factors driving the growth of the market are the growing government funding for R&D and the prevailing autoimmune diseases like Crohn’s disease and irritable bowel syndrome.
To learn more about this report, request a free sample copy
The countries analyzed in the North America immunosuppressant drugs market growth evaluation are the United States and Canada. In the United States, the cornea is the majorly transplanted tissue. More than 40,000 corneal transplants are performed every year. A substantial amount of living donations also take place every year. Liver and kidney diseases have taken more lives in the country than any other disease, with a large number of people on the waiting list for related organ transplants. Thus, the increasing demand for organ transplantation is estimated to affect market growth in a positive manner. Another major disease is the autoimmune disease that affects Americans, and is categorized as one of the top ten causes of death of women under the age of 65. The cases of autoimmune diseases are on the rise in the country. Such factors result in a lucrative environment for market growth.
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company involved in the development, discovery, sale, and manufacture of pharmaceutical products. The products are focused on treating conditions like gastroenterology, oncology, multiple sclerosis, etc. The products are offered through several categories. The product portfolio of the company includes, RINVOQ, HUMIRA, Upadacitinib, Risankizumab, etc. The company has its headquarters in North Chicago, Illinois, the United States.
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
- RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
- EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- MARKET OVERVIEW
- MARKET DYNAMICS
- DEVELOPMENT OF IMMUNOSUPPRESSANT DRUGS
- MARKET DEFINITION
- KEY DRIVERS
- INCREASE IN THE NUMBER OF AUTOIMMUNE DISORDERS
- RISE IN ORGAN TRANSPLANTATION
- GROWTH IN THE PHARMACEUTICAL INDUSTRY
- KEY RESTRAINTS
- SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS
- LACK OF AWARENESS ABOUT ORGAN DONATION
- KEY ANALYTICS
- KEY INVESTMENT INSIGHTS
- PORTER’S FIVE FORCE ANALYSIS
- BUYER POWER
- SUPPLIER POWER
- SUBSTITUTION
- NEW ENTRANTS
- INDUSTRY RIVALRY
- OPPORTUNITY MATRIX
- VENDOR LANDSCAPE
- MARKET BY DISTRIBUTION CHANNEL
- HOSPITAL PHARMACIES
- RETAIL PHARMACIES
- ONLINE PHARMACIES
- MARKET BY END-USER
- ORGAN TRANSPLANTATION
- AUTOIMMUNE DISORDERS
- OTHERS
- MARKET BY DRUG CLASS
- CORTICOSTEROIDS
- MONOCLONAL ANTIBODIES
- CALCINEURIN INHIBITORS
- MTOR INHIBITORS
- OTHERS
- GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
- UNITED STATES
- CANADA
- NORTH AMERICA
- COMPANY PROFILES
- ABBVIE INC
- ALLERGAN PLC (ACQUIRED BY ABVIE INC)
- ASTELLAS PHARMA INC
- BRISTOL-MYERS SQUIBB COMPANY
- CIPLA LTD
- REDDY’S LABORATORIES LTD
- F HOFFMANN-LA ROCHE AG
- GLAXOSMITHKLINE PLC
- INTAS PHARMACEUTICALS LTD (ACCORD HEALTHCARE LTD)
- JANSSEN PHARMACEUTICALS NV (JHONSON & JHONSON)
- MYLAN NV
- NOVARTIS INTERNATIONAL AG (SANDOZ)
- PFIZER INC
- SANOFI SA
- VELOXIS PHARMACEUTICALS
TABLE LIST
TABLE 1: MARKET SNAPSHOT – IMMUNOSUPPRESSANT DRUGS
TABLE 2: SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS
TABLE 3: TOP 15 POSITIVE NET EXPORTS COUNTRIES AND NEGATIVE NET EXPORTS FOR DRUGS & MEDICINES COUNTRIES
TABLE 4: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 5: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 6: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 7: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 8: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 9: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY CLASS, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 10: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 11: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
FIGURE LIST
FIGURE 1: DEVELOPMENT OF IMMUNOSUPPRESSANT DRUGS
FIGURE 2: KEY INVESTMENT INSIGHTS
FIGURE 3: PORTER’S FIVE FORCE ANALYSIS
FIGURE 4: OPPORTUNITY MATRIX
FIGURE 5: VENDOR LANDSCAPE
FIGURE 6: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2019
FIGURE 7: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY HOSPITAL PHARMACIES, 2019-2028 (IN $ MILLION)
FIGURE 8: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY RETAIL PHARMACIES, 2019-2028 (IN $ MILLION)
FIGURE 9: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY ONLINE PHARMACIES, 2019-2028 (IN $ MILLION)
FIGURE 10: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, GROWTH POTENTIAL, BY END-USER, IN 2019
FIGURE 11: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY ORGAN TRANSPLANTATION, 2019-2028 (IN $ MILLION)
FIGURE 12: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY AUTOIMMUNE DISORDERS, 2019-2028 (IN $ MILLION)
FIGURE 13: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 14: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, GROWTH POTENTIAL, BY CLASS, IN 2019
FIGURE 15: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY CORTICOSTEROIDS, 2019-2028 (IN $ MILLION)
FIGURE 16: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY MONOCLONAL ANTIBODIES, 2019-2028 (IN $ MILLION)
FIGURE 17: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY CALCINEURIN INHIBITORS, 2019-2028 (IN $ MILLION)
FIGURE 18: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY MTOR INHIBITORS, 2019-2028 (IN $ MILLION)
FIGURE 19: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 20: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
FIGURE 21: UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 22: CANADA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
- GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
- UNITED STATES
- CANADA
- NORTH AMERICA
- MARKET BY DISTRIBUTION CHANNEL
- HOSPITAL PHARMACIES
- RETAIL PHARMACIES
- ONLINE PHARMACIES
- MARKET BY END-USER
- ORGAN TRANSPLANTATION
- AUTOIMMUNE DISORDERS
- OTHERS
- MARKET BY DRUG CLASS
- CORTICOSTEROIDS
- MONOCLONAL ANTIBODIES
- CALCINEURIN INHIBITORS
- MTOR INHIBITORS
- OTHERS
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.